Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) EBT Margin (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed EBT Margin for 4 consecutive years, with 363.14% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 30305.0% to 363.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 42.7% through Dec 2025, down 4465.0% year-over-year, with the annual reading at 203.35% for FY2025, 20335.0% down from the prior year.
  • EBT Margin hit 363.14% in Q4 2025 for ARS Pharmaceuticals, up from 163.66% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 363.14% in Q4 2025 to a low of 206030.0% in Q2 2023.
  • Historically, EBT Margin has averaged 25847.52% across 4 years, with a median of 1061.19% in 2024.
  • Biggest five-year swings in EBT Margin: tumbled -20466276bps in 2023 and later surged 20296200bps in 2024.
  • Year by year, EBT Margin stood at 3507.94% in 2022, then plummeted by -5773bps to 206030.0% in 2023, then surged by 100bps to 60.08% in 2024, then soared by 504bps to 363.14% in 2025.
  • Business Quant data shows EBT Margin for SPRY at 363.14% in Q4 2025, 163.66% in Q3 2025, and 302.95% in Q2 2025.